The Ministry of Health, Labor and Welfare (MHLW) on November 22 proposed two rules designed to address windfall price rises enjoyed by cheaply sold generics - a problematic fallout from the current three price-band grouping rule.The rules formed part of…
TRENDS
Sales of Most Long-Listed Drugs Fall Short of Forecasts in Apr.-Sept.; Over 70% See Downward Revisions in Full-year Forecasts
Based on new drug makers’ settlements of accounts for April through September 2014, it is clear that companies are finding it more difficult to maintain earnings without launching new drugs and that global products are now driving earnings. This means…
To read the full story
TRENDS
- Sales per Drug Rep Hits Record High in FY2018 as Downsizing Speeds Up
August 30, 2019
- Chugai Running Offensive/Defensive Play towards EPS Growth Goal, Hemlibra Outpaces Target
August 9, 2019
- Japan SGLT2 Market Hits 70 Billion Yen as Combo Drugs Gain Ground
July 16, 2019
- Japan Drug Makers’ Workforce Down 1.3% in FY2018 amid Spate of Voluntary Redundancies
July 4, 2019
- Drug Makers Now Required to Boost Transparency in Exec Pay; Astellas Ups Bonus, Stock Option Ratio to 70%
July 3, 2019
A raft of new medicines will be added to Japan’s NHI price list on November 19, with a key reimbursement…
Combined sales of eight major Japanese drug makers grew nearly 26% year on year in April-September, pushed up by the acquisition of Shire by Takeda Pharmaceutical. Even excluding the industry leader, though, seven firms still collectively eked out a slight…
Indian generic maker Lupin is casting off Kyowa Pharmaceutical Industry, which it acquired in 2007. Forking over 57.4 billion yen…
As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
While the digital transformation may only be in its infancy in the pharmaceutical industry, the winds of change are here. It’s only a matter of time until customers and patients demand a higher level of service, experience, and connectivity from…